152 results match your criteria Anagen Effluvium


Azathioprine-Induced Marrow Suppression in Dermatology Patients - Analysis of 18 Patients.

Indian J Dermatol 2022 Jan-Feb;67(1):50-53

Department of Dermatology, Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra, India.

Background: Azathioprine is an immunosuppressant used to treat several immunological disorders. As a purine analog, it inhibits DNA synthesis and cell multiplication. However, marrow suppression is a serious complication associated with azathioprine. Read More

View Article and Full-Text PDF

Comparison of Dermoscopic Findings in Female Androgenetic Alopecia and Telogen Effluvium and Female Controls in a Tertiary Care Center.

J Clin Aesthet Dermatol 2022 May;15(5):29-34

Dr K. Kaur is a junior resident at the Department of Dermatology Venereology & Leprosy at Sri Guru Ram Das Institute of Medical Sciences & Research in Amritsar, India.

Background: Female androgenetic alopecia (FAGA) is a patterned hair loss caused by progressive miniaturization of hair follicles. This leads to reduction in the number and thickness of hairs, especially in the central, frontal, and parietal scalp regions. Telogen effluvium (TE) is characterized by diffuse hair loss within months of a significant systemic stressor because of premature follicular transition from the anagen to the telogen. Read More

View Article and Full-Text PDF

Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.

J Dermatol 2022 May 27. Epub 2022 May 27.

Clinical Development, Research and Development Headquarters Self-Medication, Taisho Pharmaceutical Co.Ltd, Tokyo, Japan.

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic by the World Health Organization, and COVID-19 continues to have a major impact on society. Numerous studies have reported impaired health sequelae after COVID-19 recovery, one of which is hair loss. Individuals with hair loss experience a substantial mental burden, which potentially hinders their social life. Read More

View Article and Full-Text PDF

Targeted Nutritional Supplementation for Telogen Effluvium: Multicenter Study on Efficacy of a Hydrolyzed Collagen, Vitamin-, and Mineral-Based Induction and Maintenance Treatment.

Int J Trichology 2022 Mar-Apr;14(2):49-54. Epub 2022 Apr 4.

Centre for Dermatology and Hair Diseases Professor Trüeb, Zurich-Wallisellen, Switzerland.

Background: The condition of the hair is closely related to the nutritional state. Normal supply, uptake, and transport of nutrients are of fundamental importance in tissues with a high biosynthetic activity such as the hair follicle.

Objective: The objective of the study was to evaluate the efficacy of a nutritional-based induction and maintenance treatment for telogen effluvium formulated with a combination of hydrolyzed collagen, amino acids, vitamins, and minerals. Read More

View Article and Full-Text PDF

An extract of Leontopodium alpinum inhibits catagen development ex vivo and increases hair density in vivo.

Int J Cosmet Sci 2022 May 6. Epub 2022 May 6.

Monasterium Laboratory, Münster, Germany.

Objectives: Hair loss and reduction in hair volume are hallmarks of hair disorders, such as telogen effluvium, or male or female pattern hair loss, and hair ageing, which can cause severe distress in both men and women. Common anti-hair loss drugs carry some side effects; therefore, novel, safer approaches targeting milder phenotypes are highly advocated. In this context, we investigated an extract of the alpine plant Edelweiss, Leontopodium alpinum var. Read More

View Article and Full-Text PDF

Anagen Effluvium after Neurointerventional Radiation: Trichoscopy as a Diagnostic Ally.

Skin Appendage Disord 2022 Mar 14;8(2):102-107. Epub 2021 Sep 14.

Universidad Autónoma de Nuevo León, Facultad de Medicina, Servicio de Dermatología Hospital Universitario "Dr. José Eleuterio González,", Monterrey, Mexico.

Minimally invasive procedures for vascular brain lesions are being performed more frequently. Radiation exposure caused by endovascular embolization of cerebral aneurysms may give rise to nonscarring scalp alopecia located in the treated area. Clinical and trichoscopic features of this type of alopecia are similar to alopecia areata (AA). Read More

View Article and Full-Text PDF

The role of SARS-CoV-2 infection and its vaccines in various types of hair loss.

Dermatol Ther 2022 Jun 1;35(6):e15433. Epub 2022 Apr 1.

Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.

The prevalence of hair loss has increased during COVID-19. In this study, we review the current literature on incidence and characteristics of various types of COVID-19-related and COVID-19-vaccine- related hair loss including telogen effluvium, alopecia areata, friction alopecia and anagen effluvium. Regarding most of them, the more severe the infection, the more profound and prolonged the course of alopecia. Read More

View Article and Full-Text PDF

Alopecia in patients with COVID-19: A systematic review and meta-analysis.

JAAD Int 2022 Jun 22;7:67-77. Epub 2022 Feb 22.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.

Background: COVID-19 is associated with androgenetic alopecia (AGA), telogen effluvium (TE), and alopecia areata (AA). No studies have analyzed the aggregate data to date.

Objective: We conducted a systematic review to characterize the types, incidence, timing, and clinical outcomes of COVID-19-associated alopecia. Read More

View Article and Full-Text PDF

Hair and nail manifestations of COVID-19.

J Cosmet Dermatol 2022 Apr 2;21(4):1339-1346. Epub 2022 Feb 2.

Dermatology Unit, Spallanzani Hospital, Rome, Italy.

Emerging literature evidence shows that the manifestations of the coronavirus disease 2019 (COVID-19), which is the disease caused by SARS-CoV-2, encompass alterations of the pulmonary, cardiovascular, gastrointestinal, and neurological system. Moreover, hematologic and dermatologic manifestations have been documented. The aim of this review is to summarize the dermatologic manifestations of COVID-19 involving the hair and nails in a narrative way. Read More

View Article and Full-Text PDF

Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium.

J Am Acad Dermatol 2022 05 11;86(5):e209-e210. Epub 2021 Dec 11.

Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Florida.

View Article and Full-Text PDF

Assessment of the effects of a hair lotion in women with acute telogen effluvium: a randomized controlled study.

J Eur Acad Dermatol Venereol 2021 Nov;35 Suppl 2:12-20

Medical Affairs Department, Pierre Fabre Laboratory, Lavaur, France.

Background: Telogen effluvium is a hair loss disorder occurring about 3 months after a triggering event. The acute form impairs quality of life, but spontaneous recovery usually begins 3-6 months after identification and elimination of the cause, with complete recovery taking around 12 months.

Objectives: To investigate the effectiveness and safety of a hair lotion containing creatine, acetyl tetrapeptide-2 and B vitamins for reducing hair loss in acute telogen effluvium. Read More

View Article and Full-Text PDF
November 2021

Anagen Effluvium: A Trichoscopic Analysis.

Indian Dermatol Online J 2021 Sep-Oct;12(5):786-787. Epub 2020 Sep 19.

Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.

View Article and Full-Text PDF
September 2020

Anagen effluvium and the role of trichoscopy.

Clin Exp Dermatol 2022 Mar 23;47(3):589-591. Epub 2021 Nov 23.

Dermatology Division, IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum University of Bologna, Bologna, Italy.

View Article and Full-Text PDF

Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms.

Skin Appendage Disord 2021 Jul 8;21:1-5. Epub 2021 Jul 8.

Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.

Introduction: Physicians have largely studied the cutaneous involvement of coronavirus disease 2019 (COVID-19), but only few reports have focused on telogen effluvium (TE) as a possible sequela of COVID-19. We assessed 14 cases of hair loss occurring after SARS-CoV-2 infection using trichoscopy and trichogram to investigate patterns related to COVID-19. Furthermore, we discussed possible mechanisms involved in COVID-19 TE. Read More

View Article and Full-Text PDF

Anagen Effluvium after Therapeutic Scalp Surgery: Unreported Phenomenon.

Skin Appendage Disord 2021 Jun 23;7(4):311-314. Epub 2021 Mar 23.

Dermatology, Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.

Introduction: Many procedures are performed on the scalp, such as excision of pilar and sebaceous cysts, melanocytic nevi, and reduction surgery for scarring alopecia, among others. In hair transplants, telogen effluvium is often reported 3 months after surgery; however, hair loss usually happens much earlier, around second week after the procedure, not compatible with the time required for hair to enter telogen and exogenous phases in normal conditions.

Case Reports: We report 3 cases of anagen hair loss 4 weeks after surgeries, with perilesional trichoscopy suggesting anagen effluvium, with typical signs such as black dots and exclamation hairs. Read More

View Article and Full-Text PDF

Minoxidil: a comprehensive review.

J Dermatolog Treat 2021 Jul 20:1-11. Epub 2021 Jul 20.

Mediprobe Research Inc., London, Canada.

Topical minoxidil (5% foam, 5% solution, and 2% solution) is FDA-approved for androgenetic alopecia (AGA) in men and women. Minoxidil acts through multiple pathways (vasodilator, anti-inflammatory agent, inducer of the Wnt/β-catenin signaling pathway, an antiandrogen), and may also affect the length of the anagen and telogen phases. Approximately 1. Read More

View Article and Full-Text PDF

Flame Hair: Auxiliary Trichoscopic Finding in Radiotherapy-Induced Alopecia.

Skin Appendage Disord 2021 Apr 18;7(3):224-226. Epub 2021 Feb 18.

Division of Dermatology, Department of Internal Medicine, Hospital of the clinics of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.

Radiotherapy-induced alopecia is characterized by an anagen effluvium (AE). It may be temporary or permanent, depending on the radiation dose. The diagnosis is based on clinical history and dermatologic exam with trichoscopy being auxiliary the presence of flame hair. Read More

View Article and Full-Text PDF

Association between stress and bilateral symmetrical alopecia in free-ranging Formosan macaques in Mt. Longevity, Taiwan.

Sci Rep 2021 05 27;11(1):11189. Epub 2021 May 27.

Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, 912, Taiwan, ROC.

Since 2013, a high incidence of bilateral symmetrical alopecia has been observed in free-ranging Formosan macaques (Macaca cyclopis) in Mt. Longevity, Taiwan. We hypothesized that stress induces alopecia in this population. Read More

View Article and Full-Text PDF

Analysis of Microscopic Examination of Pulled Out Hair in Telogen Effluvium Patients.

Ann Dermatol 2020 04 11;32(2):141-145. Epub 2020 Mar 11.

Department of Dermatology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

Background: Telogen effluvium (TE) is characterized by massive hair shedding and results from an abrupt conversion of anagen to telogen. Differentiation of TE with other hair disorders showing massive hair shedding is difficult.

Objective: To evaluate the morphologic characteristics of pulled out hair of TE. Read More

View Article and Full-Text PDF

A new combination of molecules for the treatment of androgenetic alopecia and telogen effluvium: a double-blind randomized, monocentric, placebo-controlled study.

Ital J Dermatol Venerol 2022 Feb 21;157(1):78-83. Epub 2021 Apr 21.

Sacred Heart Catholic University, Rome, Italy.

Background: Androgenetic alopecia (AGA) is the most frequent form of alopecia. Telogen effluvium (TE) is a common form of diffuse hair loss mainly observed in women. The aim of our study was to evaluate the efficacy of a topical trichological treatment containing a new combination of molecules for the treatment of AGA and TE. Read More

View Article and Full-Text PDF
February 2022

Recent Insight on the Management of Lupus Erythematosus Alopecia.

Clin Cosmet Investig Dermatol 2021 30;14:333-347. Epub 2021 Mar 30.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Lupus erythematosus (LE) is a chronic autoimmune condition with a wide spectrum of clinical presentations. Alopecias, both non-scarring and scarring, frequently occur in the context of LE and can assume several different patterns. Furthermore, alopecia occurring with LE may be considered LE-specific if LE-specific features are present on histology; otherwise, alopecia is considered non-LE-specific. Read More

View Article and Full-Text PDF

Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.

J Eur Acad Dermatol Venereol 2021 Jul 23;35(7):1485-1492. Epub 2021 Mar 23.

Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Topical minoxidil has been used for many years as treatment for different hair disorders. Even though it is an effective therapy, many patients show poor compliance due to the cosmesis, cost and side-effects. During the last few years, low-dose oral minoxidil has proven to be an alternative for patients with alopecia. Read More

View Article and Full-Text PDF

Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents--An Observational Clinical Study.

Clin Breast Cancer 2021 08 23;21(4):e434-e447. Epub 2021 Jan 23.

Department of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, India.

Background: Systemic chemotherapy and targeted agents are associated with various cutaneous toxicities. Even though cutaneous toxicities are manageable, it often results in treatment discontinuation and worsens the patients' quality of life.

Aim: The study aimed to determine the spectrum of cutaneous toxicities in patients receiving systemic chemotherapy and targeted agents for breast cancer patients. Read More

View Article and Full-Text PDF

Trichobiolight: A new, effective protocol in the treatment of androgenetic alopecia and telogen effluvium.

Dermatol Ther 2021 03 7;34(2):e14799. Epub 2021 Feb 7.

Department of Dermatology, University Medical Center Mainz, Mainz, Germany.

Androgenetic alopecia (AGA) with its precursor miniaturization of anagen phase (MA) and telogen effluvium (TE) represent nonscarring hair loss diseases which causes moderate to severe aesthetic and psychologic discomfort in affected people. Several therapeutic approaches have been tested through the latest decades, with different degree of success. In this study we aim to analyze the efficacy and outcome of an innovative therapeutic protocol, named TRICHOBIOLIGHT, a combination of active principles conveyed by mesotherapy directly on the scalp with a subsequent photobiostimulation session with LED light (630 nm). Read More

View Article and Full-Text PDF

What can the hair tell us about COVID-19?

Exp Dermatol 2021 02 28;30(2):288-290. Epub 2020 Dec 28.

Department of Dermatology, Universidade Federal Fluminense, Centro de Ciências Médicas, Hospital Universitário Antonia Pedro, Niterói - Rio de Janeiro, Brazil.

The novel viral pandemic coronavirus disease 2019 (COVID-19) has sparked uncertainties as to its origin, epidemiology and natural course. The study of the cutaneous manifestations of COVID-19 has evolved with the hope that they may be useful as markers for the disease, prognostication and pathogenic insights into the disease. With regard to the hair, clinicopathological correlations have remained elusive. Read More

View Article and Full-Text PDF
February 2021

Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience.

Dermatol Ther 2021 Jan 23;34(1):e14547. Epub 2020 Nov 23.

Department of Clinical and Molecular Sciences - Dermatological Clinic, Università Politecnica delle Marche, Ancona, Italy.

Telogen effluvium (TE) is one of the most common form of hair loss in women. Many triggers have been identified, as stress, drugs, trauma, endocrine disease, nutritional deficiencies, and febrile states. We report three cases of TE occurred after severe Sars-Cov-2 infection and provide our clinical management, according to Sars-Cov-2 hygiene measures. Read More

View Article and Full-Text PDF
January 2021

Cutaneous manifestations in pediatric oncology patients.

Pediatr Dermatol 2021 Jan 12;38(1):58-65. Epub 2020 Nov 12.

Dermatology Department, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.

Background/objectives: Oncology patients present with various skin manifestations related to primary disease and treatments. Although these skin toxicities are well described in adults, studies of pediatric oncology patients are limited. The objective of this study was to evaluate the cutaneous findings in pediatric oncology patients receiving chemotherapy. Read More

View Article and Full-Text PDF
January 2021

Albendazole-induced anagen effluvium: a brief literature review and our own experience.

Acta Dermatovenerol Alp Pannonica Adriat 2020 Sep;29(3):161-163

Department of Dermatology and Venereology, University of Health Sciences, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.

Albendazole is a drug commonly used for treating many parasitoses. The primary mechanism of action is inhibition of microtubule polymerization binding to β-tubulin, similar to colchicine as a microtubule formation inhibitor. It is reasonable that these two antimitotic drugs can cause side effects such as alopecia and cytopenia by a similar mechanism. Read More

View Article and Full-Text PDF
September 2020

Anagen Effluvium after Methotrexate: An Idiosyncratic Reaction.

Int J Trichology 2020 Mar-Apr;12(2):93-96. Epub 2020 May 5.

Department of Dermatology, Armed Forces Medical College, Pune, Maharashtra, India.

Low-dose methotrexate (MTX) is the backbone of treatment for extensive psoriasis vulgaris not responding to topical therapy. Since its induction for the treatment of psoriasis in the 1970, its short- and long-term side effect profile has been extensively studied. Hair loss with MTX has been reported mostly with high-dose MTX used in chemotherapy. Read More

View Article and Full-Text PDF